Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7999, a TMPRSS6 Antagonist, in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7999, a TMPRSS6 Antagonist, in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REGN-7999 (Primary) ; REGN-7999 (Primary)
  • Indications Beta-thalassaemia; Iron overload
  • Focus Adverse reactions; First in man
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 12 Dec 2023 Results exploring the safety, tolerability, pharmacokinetics, and pharmacologic effects associated with REGN7999, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 03 Nov 2023 According to a Regeneron Pharmaceuticals media release, the updated data from this study will be presented at American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.
  • 14 Sep 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top